AU2019393161A1 - USP19 inhibitors for use in therapy - Google Patents

USP19 inhibitors for use in therapy Download PDF

Info

Publication number
AU2019393161A1
AU2019393161A1 AU2019393161A AU2019393161A AU2019393161A1 AU 2019393161 A1 AU2019393161 A1 AU 2019393161A1 AU 2019393161 A AU2019393161 A AU 2019393161A AU 2019393161 A AU2019393161 A AU 2019393161A AU 2019393161 A1 AU2019393161 A1 AU 2019393161A1
Authority
AU
Australia
Prior art keywords
methyl
hydroxy
phenyl
oxo
azaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019393161A
Other languages
English (en)
Inventor
Christina Bell
Frank Burkamp
Aaron CRANSTON
Timothy Harrison
Matthew Duncan HELM
Peter Hewitt
Xavier Jacq
Mary Melissa Mcfarland
Colin O'dowd
Lauren PROCTOR
James Samuel Shane Rountree
Ewelina Rozycka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Discovery Ltd
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1819936.4A external-priority patent/GB201819936D0/en
Priority claimed from GBGB1904341.3A external-priority patent/GB201904341D0/en
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of AU2019393161A1 publication Critical patent/AU2019393161A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2019393161A 2018-12-06 2019-12-06 USP19 inhibitors for use in therapy Abandoned AU2019393161A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1819936.4 2018-12-06
GBGB1819936.4A GB201819936D0 (en) 2018-12-06 2018-12-06 Therapeutic methods
GBGB1904341.3A GB201904341D0 (en) 2019-03-28 2019-03-28 Therapeutic methods
GB1904341.3 2019-03-28
PCT/GB2019/053456 WO2020115500A1 (en) 2018-12-06 2019-12-06 Usp19 inhibitors for use in therapy

Publications (1)

Publication Number Publication Date
AU2019393161A1 true AU2019393161A1 (en) 2021-06-17

Family

ID=68887434

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019393161A Abandoned AU2019393161A1 (en) 2018-12-06 2019-12-06 USP19 inhibitors for use in therapy

Country Status (12)

Country Link
US (1) US20220016115A1 (cg-RX-API-DMAC7.html)
EP (1) EP3890737B1 (cg-RX-API-DMAC7.html)
JP (1) JP2022510700A (cg-RX-API-DMAC7.html)
KR (1) KR20210100127A (cg-RX-API-DMAC7.html)
CN (1) CN113395965A (cg-RX-API-DMAC7.html)
AU (1) AU2019393161A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021010645A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121422A1 (cg-RX-API-DMAC7.html)
IL (1) IL283687A (cg-RX-API-DMAC7.html)
MX (1) MX2021006542A (cg-RX-API-DMAC7.html)
SG (1) SG11202105911PA (cg-RX-API-DMAC7.html)
WO (1) WO2020115500A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3134564A1 (en) * 2019-05-06 2020-11-12 Lawrence Marcin Inhibiting usp19
GB202104097D0 (en) * 2021-03-24 2021-05-05 Almac Discovery Ltd Pharmaceutical compounds
GB202311227D0 (en) 2023-07-21 2023-09-06 Almac Discovery Ltd Pharmaceutical compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
WO2009072643A1 (en) 2007-12-03 2009-06-11 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use thereof
CN104174021A (zh) * 2013-05-22 2014-12-03 复旦大学附属华山医院 蛋白酶体抑制剂在制备治疗慢性低度炎症性疾病药物中的用途
TWI698436B (zh) * 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶
GB201612938D0 (en) * 2016-07-26 2016-09-07 Almac Discovery Ltd Pharmaceutical compounds
AU2018342089B2 (en) * 2017-09-26 2024-07-11 Dana-Farber Cancer Institute, Inc. Novel USP7 inhibitors for treating multiple myeloma
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
WO2020115500A1 (en) 2020-06-11
EP3890737A1 (en) 2021-10-13
IL283687A (en) 2021-07-29
EP3890737B1 (en) 2024-06-05
CA3121422A1 (en) 2020-06-11
MX2021006542A (es) 2021-07-07
BR112021010645A2 (pt) 2021-08-17
KR20210100127A (ko) 2021-08-13
US20220016115A1 (en) 2022-01-20
CN113395965A (zh) 2021-09-14
SG11202105911PA (en) 2021-07-29
JP2022510700A (ja) 2022-01-27

Similar Documents

Publication Publication Date Title
JP7295169B2 (ja) Btk阻害活性を有するピリミジン及びピリジン化合物を用いた癌の治療方法
AU2011238616B2 (en) Multisubstituted aromatic compounds as inhibitors of thrombin
AU2013243671B2 (en) Methods for improving diaphragm function
KR100971093B1 (ko) 치환된 4-아미노-2-아릴-피리미딘, 이의 제조방법 및 이를 함유하는 약제학적 제제
EP3890737B1 (en) Usp19 inhibitors for use in a method of treating obesity, insulin resistance and type ii diabetes
US10875863B2 (en) RIPK2 inhibitors and method of treating cancer with same
EP3490982A1 (en) Pharmaceutical compounds
WO2023232069A1 (zh) 一种氮杂喹啉酮类衍生物、其制备方法及用途
EA027374B1 (ru) Асимметричные мочевины и их медицинское применение
KR20140117684A (ko) 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
AU2016232191A1 (en) NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat
JP2022515630A (ja) Nav1.7およびNav1.8遮断薬としての複素環誘導体
JP4422335B2 (ja) グアニル酸シクラーゼ活性化剤としてのスルホニルアミノカルボン酸n−アリールアミド
JP2021098691A (ja) 核内受容体に対して活性の化合物
EP4587429A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compounds
US20220033397A1 (en) Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19)
US20240327382A1 (en) Pharmaceutical compounds as inhibitors of ubiquitin specific protease 19
JP7759065B2 (ja) ペンドリン抑制活性を有する新規化合物およびその医薬用途
TW201022234A (en) Pyrrolidines
AU2024300899A1 (en) Pharmaceutical compounds
WO2025108404A1 (zh) 一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途
TW202615014A (zh) 作為蛋白質酪氨酸磷酸酶抑制劑的含雙鍵取代的化合物及其應用

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ ROUNTREE, JAMES SAMUEL SHANE; HEWITT, PETER; MCFARLAND, MARY MELISSA; BURKAMP, FRANK; BELL, CHRISTINA; O'DOWD, COLIN; HARRISON, TIMOTHY; HELM, MATTHEW DUNCAN; ROZYCKA, EWELINA; CRANSTON, AARON; JACQ, XAVIER AND PROCTOR, LAUREN

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period